| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CTRV.2014.10.004 |
| P698 | PubMed publication ID | 25455730 |
| P50 | author | William M Gallagher | Q38523181 |
| Darran P O'Connor | Q60618173 | ||
| P2093 | author name string | John Crown | |
| Michael J Duffy | |||
| Patricia M McGowan | |||
| Naoise C Synnott | |||
| P433 | issue | 10 | |
| P304 | page(s) | 1153-1160 | |
| P577 | publication date | 2014-12-01 | |
| P1433 | published in | Cancer Treatment Reviews | Q1955762 |
| P1476 | title | p53 as a target for the treatment of cancer | |
| P478 | volume | 40 |
| Q40614153 | A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). |
| Q93372543 | AMP Kinase Activation Attenuates Cardiac Remodeling in Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction; Lung Epithelial Progenitor Cells in Alveolar Regeneration; and Drug Discovery and Novel Therapies for Lung Cancer |
| Q52655195 | Advances in the mechanisms of action of cancer-targeting oncolytic viruses. |
| Q59792555 | Alteration of gene expression profile in CD3 T-cells after downregulating MALT1 |
| Q41949931 | An open-label phase I dose-finding study of APR-246 in hematological malignancies. |
| Q37049848 | Anti-tumor effect of β-glucan from Lentinus edodes and the underlying mechanism |
| Q36843796 | Antiproliferative and proapoptotic effects of a pyrrole containing arylthioindole in human Jurkat leukemia cell line and multidrug-resistant Jurkat/A4 cells |
| Q36910793 | Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing |
| Q64269891 | Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer |
| Q53572837 | Association of TP53 gene polymorphisms with susceptibility of bladder cancer in Bangladeshi population. |
| Q61814935 | Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells |
| Q37576027 | Benzyl Isothiocyanate potentiates p53 signaling and antitumor effects against breast cancer through activation of p53-LKB1 and p73-LKB1 axes |
| Q36143729 | Breast Cancer Survivorship Care: Targeting a Colorectal Cancer Education Intervention |
| Q26749008 | Chemical Variations on the p53 Reactivation Theme |
| Q58695185 | Cold shock proteins: from cellular mechanisms to pathophysiology and disease |
| Q38763503 | Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters : A single-center analysis |
| Q33633277 | Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy |
| Q37604313 | Comparative analysis of Notch1 and Notch2 binding sites in the genome of BxPC3 pancreatic cancer cells |
| Q90981691 | Comutation and exclusion analysis in human tumors: A tool for cancer biology studies and for rational selection of multitargeted therapeutic approaches |
| Q38686002 | Curcumol triggers apoptosis of p53 mutant triple-negative human breast cancer MDA-MB 231 cells via activation of p73 and PUMA. |
| Q41145800 | DEOD: uncovering dominant effects of cancer-driver genes based on a partial covariance selection method |
| Q33655046 | Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site - current status and challenges |
| Q38695489 | Effect of the p53α gene on the chemosensitivity of the H1299 human lung adenocarcinoma cell line |
| Q61448020 | Epigenetic therapy for ovarian cancer: promise and progress |
| Q26800255 | Exploiting Fungal Virulence-Regulating Transcription Factors As Novel Antifungal Drug Targets |
| Q49901846 | Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing |
| Q86890952 | Genomic testing and precision medicine--What does this mean for gynecologic oncology? |
| Q38597700 | Glioblastoma targeted therapy: updated approaches from recent biological insights |
| Q36557315 | Hexokinase and phosphofructokinase activity and intracellular distribution correlate with aggressiveness and invasiveness of human breast carcinoma. |
| Q48055031 | Identification of a Triterpenoid as a Novel PPARγ Activator Derived from Formosan Plants |
| Q55264153 | Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma. |
| Q49222739 | Individual and combined effect of TP53, MDM2, MDM4, MTHFR, CCR5, and CASP8 gene polymorphisms in lung cancer |
| Q39711305 | Indolo-pyrido-isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of p53-miR34a axis |
| Q35879549 | Induction of p53-independent growth inhibition in lung carcinoma cell A549 by gypenosides |
| Q49243252 | Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy |
| Q92209964 | Inhibition of p53 and/or AKT as a new therapeutic approach specifically targeting ALT cancers |
| Q33759673 | Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads |
| Q50305761 | Integrated TCGA analysis implicates lncRNA CTB-193M12.5 as a prognostic factor in lung adenocarcinoma. |
| Q42317490 | Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition |
| Q41023571 | MDM2-MDM4 molecular interaction investigated by atomic force spectroscopy and surface plasmon resonance |
| Q47098435 | MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway |
| Q37627678 | MiR-328 May be Considered as an Oncogene in Human Invasive Breast Carcinoma. |
| Q28066904 | Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment |
| Q50943660 | Molecular Mechanisms Underlying the Inhibitory Effects of Qingzaojiufei Decoction on Tumor Growth in Lewis Lung Carcinoma. |
| Q39393193 | Molecularly targeted therapies for p53-mutant cancers |
| Q36077810 | Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations |
| Q38746991 | Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? |
| Q38417021 | New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer |
| Q38885495 | Noncoding RNAs in Therapeutic Resistance of Cancer |
| Q38824781 | Nucleolus-derived mediators in oncogenic stress response and activation of p53-dependent pathways |
| Q36376797 | OVA12 promotes tumor growth by regulating p53 expression in human cancer cells |
| Q26798218 | Origins, genetic landscape, and emerging therapies of small cell lung cancer |
| Q37696259 | PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK |
| Q33439682 | Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. |
| Q37130539 | Primary cancer cell culture: mammary-optimized vs conditional reprogramming |
| Q57480180 | Prognostic value of DKK2 from the Dickkopf family in human breast cancer |
| Q36021093 | Proteomic analysis of stromal proteins in different stages of colorectal cancer establishes Tenascin-C as a stromal biomarker for colorectal cancer metastasis |
| Q37190411 | Repeated PM2.5 exposure inhibits BEAS-2B cell P53 expression through ROS-Akt-DNMT3B pathway-mediated promoter hypermethylation |
| Q55375930 | Role of Kruppel-like factor 4 in regulating inhibitor of apoptosis-stimulating protein of p53 in the progression of gastric cancer. |
| Q42367187 | Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study |
| Q64937484 | TP53 mutations in epithelial ovarian cancer. |
| Q57167704 | Targeted Therapies in the Treatment of Sarcomas |
| Q26770856 | Targeting Oncogenic Mutant p53 for Cancer Therapy |
| Q37702768 | Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin |
| Q36347511 | Targeting Transcription Factors in Cancer |
| Q91643844 | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors |
| Q47215879 | The Forty-Sixth Euro Congress on Drug Synthesis and Analysis: Snapshot †. |
| Q91884641 | The development of the concept of ferroptosis |
| Q38957038 | The future role of molecular staging in gynecologic cancer |
| Q64081177 | The obesity paradox in lung cancer: is there a missing biological link? |
| Q39034765 | The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment |
| Q37269146 | Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations |
| Q40284258 | p53 Restoration in Induction and Maintenance of Senescence: Differential Effects in Premalignant and Malignant Tumor Cells. |
| Q36688072 | p53 inhibits the expression of p125 and the methylation of POLD1 gene promoter by downregulating the Sp1-induced DNMT1 activities in breast cancer |
| Q36568079 | p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines |
| Q33873143 | β2-AR activation induces chemoresistance by modulating p53 acetylation through upregulating Sirt1 in cervical cancer cells |
Search more.